Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone-Inhibitory Effect of Octreotide after Growth Hormone-Releasing Hormone Stimulation

Plain-language guide to PMID 34599040 (2021): double-blind randomized controlled trial study of Octreotide and GHRH (Growth Hormone-Releasing Hormone).

Key Facts

PMID: 34599040
Journal: The Journal of pharmacology and experimental therapeutics
Year: 2021
Study type: Randomized Controlled Trial
Authors: Iida H et al. (12 authors)
DOI: 10.1124/jpet.121.000769

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Octreotide and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.

Despite available surgical and medical therapies, suitable treatments for acromegaly are still lacking.

Efficient drug development requires an understanding of the exposure-response (E-R) relationship based on nonclinical and early clinical studies.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Octreotide.

A placebo (an inactive look-alike) gave the Octreotide group a baseline to be compared against.

Each person switched between Octreotide and the comparison at some point, usually with a gap in between.

What Was Measured

The researchers evaluated the E-R relationship of the growth hormone (GH)-inhibitory effect of the somatostatin analog octreotide under growth hormone-releasing hormone + arginine stimulation in healthy participants and compared the results with historical data for patients with acromegaly.

The subject headings attached to it are Acromegaly, Forecasting, Growth Hormone-Releasing Hormone, Macaca fascicularis, Octreotide, Rats and Rats, Sprague-Dawley.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide and GHRH (Growth Hormone-Releasing Hormone).

The publication is from 2021 (The Journal of pharmacology and experimental therapeutics), a journal based in Netherlands.

More context: the Octreotide compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.

Our Notes on the Compounds

Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.

GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.